Sign Up to like & get
recommendations!
1
Published in 2017 at "Cancer Research"
DOI: 10.1158/1538-7445.am2017-3659
Abstract: Patients diagnosed with acute myeloid leukemia (AML) may not be eligible for curative intensive treatment due to co-morbidity factors or age. Here we report results of 5 AML patients in morphological remission after incomplete induction/consolidation…
read more here.
Keywords:
aml patients;
prame;
specific immune;
immune responses ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-142691
Abstract: Introduction: The addition of gemtuzumab ozogamicin (GO) to 7+3 chemotherapy for newly diagnosed acute myeloid leukemia (AML) has been shown to significantly improve event-free survival (EFS) for cytogenetically favorable-risk AML, with marginal benefit for intermediate-risk…
read more here.
Keywords:
risk;
adverse risk;
membership entity;
risk pts ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2021 at "Blood advances"
DOI: 10.1182/bloodadvances.2020003159
Abstract: CPX-351 is a liposomal formulation of cytarabine and daunorubicin approved for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (MRC-AML). We retrospectively analyzed the efficacy and…
read more here.
Keywords:
high risk;
real life;
cpx 351;
aml ... See more keywords